Jens Aarøe

Medicine and Dentistry

1. Patient 100%
2. Stent 94%
3. Inpatient 70%
4. Rapamycin 58%
5. Percutaneous Coronary Intervention 40%
6. Stenting 35%
7. Follow up 34%
8. ST Segment Elevation Myocardial Infarction 31%
9. Umirolimus 30%
10. Lesion 27%
11. Primary Percutaneous Coronary Intervention 26%
12. Zotarolimus 26%
13. Polymer 26%
14. Coronary Artery 22%
15. Therapeutic Procedure 22%
16. Myocardial Infarction 18%
17. Percutaneous Aortic Valve Replacement 17%
18. Diabetes Mellitus 14%
19. Diabetes 14%
20. Drug-Eluting Stent 14%
21. Noninferiority Trial 14%
22. Pump 13%
23. Everolimus 13%
24. Exercise 13%
25. Telerehabilitation 13%
26. Coronary Bifurcation Lesion 11%
27. Target Lesion 10%
28. Revascularization 10%
29. Stent Thrombosis 10%
30. Angiography 9%
31. Acute Heart Infarction 9%
32. Hazard Ratio 9%
33. Paclitaxel 9%
34. Randomized Controlled Trial 8%
35. off Pump Coronary Surgery 8%
36. Intravascular Ultrasound 8%
37. Elderly Patient 8%
38. Embolization 8%
39. Major Adverse Cardiac Event 8%
40. Mortality 8%
41. Hospital 7%
42. Apoplexy 7%
43. Target Lesion Revascularization 7%
44. Age 7%
45. Coronary Angiography 7%
46. Quality of Life 6%
47. Graft Patency 6%
48. Heart Death 6%
49. Artery 5%
50. Coronary Artery Bypass Graft 5%